The impact of oral contraceptives on cardiometabolic parameters
- 154 Downloads
There is much controversy regarding the use of oral contraceptive pills (OCPs) on cardiometabolic parameters, which is why this longitudinal population-based study was conducted to assess the impact of OCP use and its duration on cardiometabolic factors.
Of 5532 reproductive-aged participants of the Tehran lipid and glucose study, 3160 women who met our inclusion criteria were subdivided according to the duration of OCPs consumption into four sub-groups: (1) Non-users; (2) <11 month users; (3) 12–35 month users, and (4) ≥36 month users, and their cardiometabolic parameters were compared.
No statistical significant differences were observed between the cardiometabolic parameters of these sub-groups, after further adjustment for confounding factors including age, parity, and education, except for mean low-density lipoprotein-cholesterol which was significantly higher in women who used OCPs for >36 months in comparison to non-OCP users. The odds ratio of hypercholesterolemia was significantly higher in women who used OCPs for >36 months in comparison to non-OCP users; being 1.5 times higher than non-users (95 % CI 1.01–2.2).
Results showed that if used for less than 3 years, OCPs have no cardiometabolic effects.
KeywordsLipoproteins Cardiovascular risk factors Metabolic syndrome Hypertension Contraceptive pills Tehran lipid and glucose study (TLGS)
We are indebted to all the study participants for the substantial time and effort contributed to this study. Acknowledgments are also due to the research staff at the (TLGS) Unit and personnel of the Research Endocrine Laboratory. The authors wish to thank Ms. N. Shiva for critical editing of English grammar and syntax of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that there are no competing interests and that the source of funding is independent of the objectives and results found in this study.
Approval of the ethical committee of the research institute for endocrine sciences was obtained for the study, and written consents were obtained from all study participants.
The written inform consent was obtained from all individual participants included in the study.
- 3.WHO (1998) Cardiovascular disease and steroid hormone contraception. Tech Rep Ser 877:89Google Scholar
- 16.http://www.who.int/mediacentre/factsheets/fs355/en/. Accessed Jan 2015
- 17.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefPubMedGoogle Scholar
- 20.Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V (2006) Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Fertil Steril 85(5):1425–1431CrossRefPubMedGoogle Scholar
- 36.Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R (2004) A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 69(4):271–278CrossRefPubMedGoogle Scholar
- 37.Tehrani FR (2006) Contraception use behavior of Iranian women (5 selected provinces of Iran), Iran. Report No.: final research project reportGoogle Scholar